Johnson & Johnson (NYSE: JNJ) finished Thursday’s regular session lower even as the broader market moved higher, then ticked modestly upward in after-hours trading—leaving investors with a familiar year-end setup: solid pipeline/MedTech progress on one side, and talc litigation headlines on the other.
JNJ stock price after the bell: the key numbers investors are watching tonight
JNJ shares closed the regular session at $208.31, down $2.02 (-0.96%), and were slightly higher after hours at about $208.65 (+0.16%) in early evening trading.
A few additional “snapshot” metrics help frame where JNJ sits heading into Friday’s open:
- Day’s trading range: roughly $207.76 to $211.06
- 52-week range: roughly $140.68 to $215.19 (about 3.2% below the 52-week high)
- Market cap: about $502B
- Dividend yield (as displayed by Investing.com): about 2.5%
On a day when the S&P 500 rose and the Dow ended modestly higher, JNJ’s decline stood out as a defensive name lagging the tape.
The news driving Johnson & Johnson coverage today
1) FDA clearance expands J&J MedTech’s neurovascular footprint (TRUFILL n‑BCA)
The biggest company-specific headline dated today came out of J&J’s MedTech business.
Johnson & Johnson MedTech announced that the U.S. FDA approved an expanded indication for its TRUFILL n‑BCA Liquid Embolic System to support embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and chronic subdural hematoma (cSDH)as an adjunct to surgery.
The company also highlighted why investors should care clinically:
- cSDH often affects older adults and people on anticoagulation therapy; while surgery is a standard approach, recurrence estimates range from 10% to 20%.
- The expanded indication is supported by the MEMBRANE randomized controlled trial, which J&J said showed the device was superior in effectiveness versus standard of care for MMA embolization and demonstrated safety in treating cSDH.
- J&J noted TRUFILL n‑BCA has been used in neurovascular embolization for over 25 years and was originally FDA-approved in 2000.
Market takeaway: approvals like this can be incremental rather than instantly “needle-moving” for a company JNJ’s size, but they reinforce J&J’s strategy of stacking smaller wins across MedTech while the pharma portfolio continues to refresh.
2) Rybrevant moves from infusion chair to injection: a convenience and capacity story (RYBREVANT FASPRO)
While the company press release is dated Dec. 17, the development remained heavily discussed in today’s news cycle and analysis.
Johnson & Johnson said the FDA approved RYBREVANT FASPRO (amivantamab + hyaluronidase) as a subcutaneous option for patients with EGFR-mutated non-small cell lung cancer (NSCLC), and that it is approved across all indications of IV RYBREVANT.
What stood out in J&J’s own description:
- Administration time reduced from “several hours” to about five minutes. JNJ.com
- Administration-related reactions reported at 13% in the subcutaneous arm vs 66% in the IV arm (per the company’s summary).
- The approval is tied to results from the Phase 3 PALOMA-3 study, which the company said supported pharmacokinetic endpoints and provided supportive outcomes data.
A Zacks analysis published today emphasized the same investor-friendly angles: reduced chair time, improved convenience, and the potential for broader adoption now that subcutaneous administration is available.
Market takeaway: in big-cap pharma, “new-to-the-market” isn’t the only catalyst—improving how a therapy is delivered can expand real-world utilization by reducing friction for both patients and clinics.
3) Talc litigation remains a headline risk—even when the stock isn’t reacting violently
Talc-related litigation has been a long-running overhang for JNJ, and it re-entered headlines again today.
A Reuters report (dated Dec. 13) said a California jury ordered Johnson & Johnson to pay $40 million to two women who alleged ovarian cancer linked to long-term use of talc-based baby powder, and noted the company said it would appeal while disputing the claimed link between talc and cancer.
The Associated Press reported the same verdict amount and likewise said J&J denies the claims and plans to appeal.
A PR Newswire release distributed today also highlighted the verdict and its implications, though investors should note this was distributed via a law firm communications channel rather than a neutral wire story.
Market takeaway: for JNJ, litigation headlines often influence sentiment as much as near-term financial models—particularly if investors are trying to handicap the path toward global resolution, appeal outcomes, and any future settlement frameworks.
Today’s forecasts and analyst views: what Wall Street is signaling into Friday
Goldman raises its target—while the broader consensus stays clustered near current levels
One of the most notable “today” updates on the Street: Goldman Sachs raised its price target on Johnson & Johnson to $240 from $213 and kept a Buy rating, according to TheFly via TipRanks. TipRanks
That new target is meaningfully above tonight’s after-hours price (roughly 15% upside from ~$208), which helps explain why even a small positive drift after hours can draw attention: investors often look for confirmation that good operational headlines are being “validated” by analysts.
At the same time, broader consensus targets still imply a more muted outlook. For example, MarketBeat lists an average 12‑month price target near $210.25 (roughly ~1% upside around tonight’s levels), with targets spanning $153 to $240.
Market takeaway: dispersion is the story—some analysts see JNJ as a durable compounder deserving higher multiples, while the consensus view suggests the stock is closer to fairly valued after a strong 2025 run and with litigation uncertainty still in the background.
What to know before the stock market opens tomorrow (Friday, Dec. 19, 2025)
1) Don’t overread the after-hours move—watch for follow-through in premarket liquidity
JNJ’s after-hours uptick (about +0.16%) is modest and could be driven by thin trading rather than a fresh institutional view.
What matters more heading into the opening print is whether buyers show up in size—or whether the stock continues to drift as investors rebalance into year-end.
2) FDA headline digestion can be delayed in megacaps—watch relative strength vs. healthcare peers
Both the TRUFILL indication expansion (MedTech) and the Rybrevant subcutaneous approval (Innovative Medicine) are the kinds of catalysts that can show up gradually, especially as analysts update revenue curves and commercial assumptions over days—not hours.
A practical “tomorrow morning” tell: whether JNJ can outperform the healthcare complex early, even if the broader market is mixed.
3) Options expiration dynamics could amplify moves—even in a low-drama stock like JNJ
Friday, Dec. 19, 2025, is one of the market’s quarterly “triple witching” dates (when multiple derivatives categories expire), which can increase volatility and volume in the overall market. TastyLive
This doesn’t automatically mean JNJ will swing sharply, but it can create mechanical price action around heavily trafficked strikes—something short-term traders and hedgers watch closely.
4) Keep the calendar in view: next major JNJ catalyst is January earnings
Johnson & Johnson’s next major scheduled event is its Fourth Quarter 2025 earnings call, listed for Jan. 21, 2026 at 8:30 a.m. ET. Johnson & Johnson Investor Relations
That’s close enough that “positioning ahead of earnings season” can begin to influence flows, particularly for institutions managing year-end risk.
5) Year-end trading conditions: the market stays open, but holiday schedule can affect liquidity
A Reuters report published today said major U.S. exchanges plan to remain open on Dec. 24 and Dec. 26 (with an early close on Dec. 24) despite a federal government closure order for those dates. Reuters
For investors, the practical implication is that liquidity can get choppy as market participants head into holiday mode—sometimes making “normal” pullbacks look sharper than they are.
Bottom line for JNJ stock tonight
JNJ heads into Friday’s session near $208–$209 after hours, with the tape balancing three forces:
- Operational momentum: tangible FDA wins across MedTech and oncology delivery innovation
- Analyst positioning: at least one prominent upgrade in targets (Goldman to $240), but a broader consensus that sits closer to today’s price
- Headline risk: talc litigation remains active, and while the market has learned to “absorb” these developments, they can still shape valuation and sentiment at the margin Reuters+1
